Targeting multidrug resistant tumor cells with a recombinant single-chain Fv fragment directed to P-glycoprotein

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 864-872

  Niv, Revital ^a   Assaraf, Yehuda G ^a   Segal, Dina ^a   Pirak, Esther ^a   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Multidrug resistance; P glycoprotein; Recombinant immunotoxin; Single chain Fv

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN P; IMMUNOTOXIN; MONOCLONAL ANTIBODY; RECOMBINANT IMMUNOGLOBULIN FV FRAGMENT; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; MICE; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; RECOMBINANT PROTEINS;

EID: 0035892370     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1552     Document Type: Article

References (50)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary mutants with reduced colchicine permeability
3. Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells
4. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
5. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia
6. Expression of a multidrug resistance gene in human cancers
7. The St. Jude Workshop on methods to detect P-glycoprotein-associated multidrug resistance: Findings and consensus recommendations
8. Monoclonal antibodies to P-glycoprotein: Preparation and applications to basic and clinical research
9. Recombinant immunotoxins
10. Immunotoxins for the treatment of B cell lymphomas
11. Antibody engineering for targeted drug delivery: Applications for recombinant Fv immunotoxins and Fv fragments in cancer therapy and diagnosis
12. Signaling antibodies in cancer therapy
13. Bispecific antibodies in cancer therapy
14. Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in E. coli
15. Single-chain antigen-binding proteins
16. Single-chain Fvs
17. Man-made antibodies
18. Immunotoxins in cancer therapy
19. Delivery of molecular medicine to solid tumors
20. Technetium-99m labeling and biodistribution of Anti-Tac disulfide-stabilized Fv fragment
21. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug resistant cells
22. A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219: Design, expression and crystal structure at 2.4 Å resolution
23. Multidrug resistance in ovarian cancer
24. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells
25. Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
26. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate
27. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
28. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin and vinblastine
29. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells
30. Continuous cultures of fused cells secreting antibody of predefined specificity
31. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
32. A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies
33. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies
34. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
35. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
36. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin
37. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
38. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors
39. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
40. Phase I trail of recombinant immunotoxin anti-tac(Fv)-PE38 (LMB-2) in patients with hematologcal malignancies
41. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
42. The selection of intracellular antibodies
43. Intracellular antibodies: Development and therapeutic potential
44. Phenotypic knock-out of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor
45. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells
46. Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies
47. Structural, mechanistic and clinical aspects of MRP1
48. Multidrug resistance: A solvable problem?
49. Overcoming multi-drug resistance using an intracellular anti-MDR1 sFv